全文获取类型
收费全文 | 546篇 |
免费 | 33篇 |
国内免费 | 45篇 |
专业分类
儿科学 | 49篇 |
妇产科学 | 4篇 |
基础医学 | 44篇 |
口腔科学 | 13篇 |
临床医学 | 87篇 |
内科学 | 122篇 |
皮肤病学 | 8篇 |
神经病学 | 27篇 |
特种医学 | 130篇 |
外科学 | 28篇 |
综合类 | 20篇 |
预防医学 | 19篇 |
眼科学 | 7篇 |
药学 | 50篇 |
中国医学 | 1篇 |
肿瘤学 | 15篇 |
出版年
2019年 | 2篇 |
2018年 | 5篇 |
2016年 | 1篇 |
2015年 | 4篇 |
2014年 | 9篇 |
2013年 | 13篇 |
2012年 | 5篇 |
2011年 | 5篇 |
2010年 | 25篇 |
2009年 | 22篇 |
2008年 | 8篇 |
2007年 | 34篇 |
2006年 | 7篇 |
2005年 | 8篇 |
2004年 | 5篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 7篇 |
2000年 | 9篇 |
1999年 | 12篇 |
1998年 | 43篇 |
1997年 | 33篇 |
1996年 | 37篇 |
1995年 | 24篇 |
1994年 | 17篇 |
1993年 | 21篇 |
1992年 | 14篇 |
1991年 | 10篇 |
1990年 | 17篇 |
1989年 | 31篇 |
1988年 | 33篇 |
1987年 | 23篇 |
1986年 | 19篇 |
1985年 | 17篇 |
1984年 | 8篇 |
1983年 | 11篇 |
1982年 | 9篇 |
1981年 | 6篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 7篇 |
1977年 | 14篇 |
1976年 | 6篇 |
1975年 | 6篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有624条查询结果,搜索用时 0 毫秒
621.
Kaori Kadoyama Akiko Kuwahara Motohiro Yamamori JB Brown Toshiyuki Sakaeda Yasushi Okuno 《Journal of experimental & clinical cancer research : CR》2011,30(1):1-6
Background
Cancer-testis antigens (CTAs) are suitable targets for cancer-specific immunotherapy. The aim of the study is to investigate the expression of CTAs in intrahepatic cholagiocarcinoma (IHCC) and evaluate their potential therapeutic values.Methods
Eighty-nine IHCC patients were retrospectively assessed for their expression of CTAs and HLA Class I by immunohistochemistry using the following antibodies: MA454 recognizing MAGE-A1, 57B recognizing multiple MAGE-A (MAGE-A3/A4), E978 recognizing NY-ESO-1, and EMR8-5 recognizing HLA class I. The clinicopathological and prognostic significance of individual CTA markers and their combination were further evaluated.Results
The expression rates of MAGE-A1, MAGE-A3/4 and NY-ESO-1 were 29.2%, 27.0% and 22.5%, respectively. The concomitant expression of CTAs and HLA class I antigen was observed in 33.7% of the IHCC tumors. We found that positive MAGE-3/4 expression correlated with larger tumor size (≥ 5 cm), tumor recurrence and poor prognosis. Moreover, we identified 52 cases (58.4%) of IHCC patients with at least one CTA marker expression, and this subgroup displayed a higher frequency of larger tumor size and a shorter survival than the other cases. Furthermore, expression of at least one CTA marker was also an independent prognostic factor in patients with IHCC.Conclusion
Our data suggest that specific immunotherapy targeted CTAs might be a novel treatment option for IHCC patients. 相似文献622.
Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin 总被引:1,自引:0,他引:1
Previously we showed that starvation of HL-60 promyelocytic leukemia cells for a single essential amino acid induced irreversible differentiation into more mature monocyte-like cells. Although not an essential amino acid, glutamine is important in the growth of normal and neoplastic cells. The glutamine analogue, alpha S,5S-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin) inhibits several glutamine-utilizing enzymes and therefore depletes cells of certain metabolic end products. The current study was designed to examine in vitro the effects of acivicin on growth and differentiation of several established human myeloid leukemia cell lines, including the HL-60 cell line, and of freshly isolated cells from patients with acute nonlymphocytic leukemia (ANLL). Four-day culture of HL-60 cells with acivicin at concentrations of 0.1 to 10.0 micrograms/mL (0.56 to 56 nmol/L) decreased cell growth by 33% to 88% as compared with untreated control cells. Viability of cells was greater than 92% for untreated cells and 93% to 41% for acivicin-treated cells. Cells treated with acivicin differentiated along a monocytic pathway as shown by increased H2O2 production and alpha-naphthyl butyrate esterase (NSE) content. Differentiation was time and dose dependent, and was irreversible. Changes in H2O2 production and NSE content were partially abrogated by co-culture with 10 mmol/L exogenous cytidine and guanosine but not by co-culture with other nucleosides or glutamine. At these concentrations of acivicin, differentiation was associated with expression of the N- formyl-methyl-leucyl-phenylalanine-receptor (FMLP-R) on 8% to 29% of cells as compared with 8% for control cells. Acivicin potentiated the differentiating effects of interferon-gamma, tumor necrosis factor, dihydroxyvitamin D3, dimethylsulfoxide, and retinoic acid. Culture of cells from the U937 (monoblastic), K562 (erythroleukemia), and KG-1 (myeloblastic) cell lines resulted in decreased growth and viability, but not consistently in differentiation. Acivicin decreased survival of freshly isolated ANLL cells and increased their H2O2 production and NSE content. These results suggest that the glutamine analogue acivicin may be useful as a differentiating agent with antileukemia activity in patients with ANLL. 相似文献
623.
624.